肝硬化
对偶(语法数字)
中医药
医学
重症监护医学
传统医学
替代医学
内科学
病理
哲学
语言学
作者
Y Q Li,Feng Yan,X B Wang,Ke Shi,Yali Liu,Yali Liu
出处
期刊:PubMed
日期:2025-08-20
卷期号:33 (8): 721-727
标识
DOI:10.3760/cma.j.cn501113-20250401-00115
摘要
Liver cirrhosis is the terminal stage of chronic liver disease. Minimizing complications of liver cirrhosis and the occurrence of liver cancer has become an important goal for liver cirrhosis treatment. The primary etiology leading to liver cirrhosis is chronic hepatitis B infection. "Dual-anti therapy" refers to the combination of anti-viral and anti-fibrosis treatment, which is the characteristic and advantage of the integration of Chinese and Western medicine. The article elaborates on the concept and strategies of "dual antibody therapy" based on evidence-based medicine and introduces the research progress in terms of representative anti-fibrotic Chinese patent medicines for reversing liver cirrhosis, reducing the occurrence of hepatocellular carcinoma, and loweri ng portal hypertension and its complications and others, revealing that dual antibody therapy can clinically facilitate dual reduction" (reducing both liver cancer and complications of cirrhosis). Additionally, it analyzes and summarizes the mechanism of action of anti-fibrotic Chinese patent medicines and prospects of a new model of liver cirrhosis treatment combining Chinese and Western medicine, thereby providing novel ideas for the prevention and treatment of clinical liver diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI